Argenx Just Cracked Open a New Market (With One Asterisk)

The DM subgroup told a different story. Patients improved by 14.5 points over placebo, which sounds great on paper. But the p-value was 0.1093, meaning it didn't reach statistical significance. In clinical trial terms, that's like shooting a free throw that rattles around the rim and pops out. Close, but it doesn't count on the scoreboard.

So the overall trial succeeded. One subtype nailed it. The other one... didn't quite get there.

Wall Street Liked It Anyway

Investors decided the glass was more than half full. Argenx shares surged approximately 16–17% on Monday after the data dropped. One early report had the stock up 8.9% at the open before the rally kept building.

Leerink analyst Thomas Smith called it a "positive outcome" and zeroed in on the IMNM results specifically, noting the massive unmet need in a patient population with no approved options. RBC Capital Markets' Luca Issi also reacted positively, suggesting the DM miss could simply reflect a small sample size rather than a real lack of efficacy.

The logic: if your combined population clears the bar and one subtype looks stellar, the regulatory path is still very much alive.

Why This Matters Beyond One Trial

Vyvgart belongs to a class called FcRn blockers. These drugs work by lowering levels of harmful antibodies in the blood (the same antibodies driving the autoimmune attack). Think of FcRn as a recycling station that keeps antibodies circulating longer than they should; blocking it essentially takes out the trash faster.

Argenx has been on a tear expanding Vyvgart's reach. The drug is already approved for generalized myasthenia gravis across all serotypes in the U.S., chronic inflammatory demyelinating polyneuropathy (CIDP) in the U.S. and Europe, and immune thrombocytopenia in Japan. Autoimmune myositis would be the next domino.

And argenx isn't done. The company has positive Phase 3 data in ocular myasthenia gravis and plans to file for that indication too. Every new approval widens the moat around a franchise that's already the clear leader in the FcRn space.

The Competition Is Getting Crowded

Argenx doesn't have this market to itself anymore. UCB's rozanolixizumab was the second FcRn blocker approved, competing mainly in myasthenia gravis. Then Johnson & Johnson crashed the party in April 2025 when nipocalimab got FDA approval for gMG in adults and adolescents.

The FcRn inhibitor market hit roughly $2.2 to $2.4 billion in 2025, and it's still growing. Analysts project argenx will hold the dominant share through 2026 thanks to its first-mover advantage and broader indication coverage, but the field is shifting from a near-duopoly into a genuine multi-player race.

That's exactly why myositis matters so much strategically. Each new indication is another lane where argenx can run ahead of competitors who haven't even started their trials yet.

The Regulatory Question Mark

The big open question: what does argenx do about dermatomyositis?

They could file based on the combined dataset alone and let regulators decide if the overall win is enough. They could also run a larger follow-on study specifically in DM to nail down the statistics.

For IMNM patients, the path looks much cleaner. A statistically significant result in a disease with no approved therapies is about as straightforward a regulatory case as you'll find in rare disease.

The Bottom Line

Argenx delivered a win where it mattered most: in a patient population that's been waiting years for something better than steroids and crossed fingers. The DM miss adds complexity, but it doesn't derail the story. If anything, it gives the company two shots at a filing strategy (combined or IMNM-only) while competitors are still designing their trials.

For the roughly 14 to 21 out of every 100,000 Americans living with some form of autoimmune myositis, the calculus is simpler. A drug that works in four weeks and holds up for a year, even during steroid tapering, is exactly what the field has been missing. The asterisk is Wall Street's problem. The patients just want the drug.

Amylyx's Unlikely Comeback Started With a Sugar Crash

Amylyx was left for dead after its ALS drug imploded. Two years later, a $35 million acquisition just delivered Phase 3 data so strong it could create the first approved treatment for a post-surgical complication nobody's been able to fix.